This case report details a 56-year-old woman with IDH-wildtype glioblastoma exhibiting a rare MEF2D-NTRK1 gene fusion. The findings highlight the molecular characterization and treatment strategies employed, including the use of tyrosine kinase inhibitors.
Background
Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis. The presence of gene fusions, such as MEF2D-NTRK1, is rare but may influence treatment decisions. Understanding the molecular profile of GBM can guide personalized therapeutic approaches.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
The patient was diagnosed with glioblastoma, IDH-wildtype, CNS WHO Grade 4.
Next-generation sequencing revealed a rare MEF2D-NTRK1 gene fusion.
The patient underwent subtotal resection followed by concurrent temozolomide and radiotherapy.
Various tyrosine kinase inhibitors were considered for potential treatment, including entrectinib and larotrectinib.
The report discusses the potential for resistance to tyrosine kinase inhibition in this context.
Clinical Implications
The identification of rare gene fusions in glioblastoma may necessitate tailored treatment strategies. Clinicians should consider molecular profiling to inform therapeutic decisions, especially in cases with unique genetic alterations.
Conclusion
This case underscores the importance of molecular characterization in glioblastoma and the potential role of targeted therapies in managing rare gene fusions.
